| Literature DB >> 35492945 |
Wenjing Sun1, Yiran Jin2, Shuai Guan2, Mengxin Yang1, Miaoting Zhang1, Jiali Hou1, Yingfeng Du1.
Abstract
Glaucocalyxin A (GLA) belongs to the natural ent-kauranoid diterpenoids family with antitumor, antifibrotic, anticoagulative, antioxidant, and anti-AD effects. In this study, ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) system was applied to observe probable metabolites of GLA in vitro and in vivo firstly. The mass data were respectively obtained by two typical acquisition methods, 'data-dependent acquisition' (DDA) and 'data-independent acquisition' (DIA) modes. The combinations can not only guarantee sensitivity but also capture more precursor ions and MS/MS spectra. Then, multiple data processing techniques were applied to hunt metabolites rapidly. As a result, 32 phase I metabolites of different structures and 6 phase II metabolites were identified, including 25, 18, 17 and 7 in rat urine, feces, bile, and plasma, respectively. Besides, under the action of rat intestinal flora (RIF), 7 metabolites were detected. In the study, the main bio-transformations were oxidation and demethylation. Conjugation with methylation, sulfate, and glucuronide produced phase II metabolites. This study laid the foundation for the further study of the pharmacological effects of GLA and was conducive to mechanism research. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35492945 PMCID: PMC9050391 DOI: 10.1039/c9ra06830a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
The parameters of MS and MS/MS analysis
| DDA (negative) | DIA (negative) | ||
|---|---|---|---|
| Different parameters | Accumulation time of MS (ms) | 200 | 430 |
| Accumulation time of MS/MS (ms) | 100 | 60 | |
| The number of isolation windows | 0 | 28 | |
| The wide of isolation windows (Da) | 0 | 26 | |
| The cycle time (s) | 1.0499 | 1.2973 | |
| The cycles | 1772 | 1434 | |
| Common parameters | Declustering potential (eV) | −60 | −60 |
| Collision energy of MS/MS (eV) | −35 | −35 | |
| Collision energy spread (eV) | −15 | −15 | |
| Mass of TOF (Da) | 100–800 | 100–800 | |
| Mass of MS/MS (Da) | 60–800 | 60–800 | |
| Ion spray voltage floating (V) | −4500 | −4500 | |
| Nebulizing gas (psi) | 55 | 55 | |
| Heater gas (psi) | 55 | 55 | |
| Curtain gas (psi) | 35 | 35 | |
| Turbo spray temperature (°C) | 550 | 550 | |
| Mass acquisition time (min) | 30 | 30 |
Fig. 3TIC for the group in vitro by DDA. (Panel A: the RIF sample group; Panel B: blank B group; Panel C: blank C group.)
Fig. 1Chemical structure of GLA.
Fig. 2The MS/MS spectrum of deprotonated GLA and its fragmentation pathway.
Fig. 8TIC for the experimental group in rat plasma by two acquisitions. (Panel A: by DDA mode; Panel B: by DIA mode.)
Fig. 5The proposed GLA metabolic profiles in vitro and in vivo.
Identification of metabolites appeared in urine, feces, bile, plasma and rat intestinal floraa
| Compound ID | Formula | [M − H]− ( |
| Error (ppm) | Fragment ions | Potential pathway | Clog | RIF | U | F | B | P |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M0 | C20H28O4 | 331.1918 | 13.41 | 0.9 | 331.1918, 313.1819, 297.1504, 285.1857, 269.1898, 255.1382, | Parent | 1.8834 | + | + | + | + | + |
| M1 | C20H26O3 | 313.1818 | 26.78 | 2.5 | 313.1818, 285.1135, 269.1193, 131.0494, | Loss of water | 1.8972 | + | ||||
| M2 | C20H26O3 | 313.1819 | 27.12 | 3.1 | 313.1819, 285.1165, 269.1205, | Loss of water | 2.3082 | + | ||||
| M3 | C19H26O4 | 317.1765 | 28.08 | 2.1 | 317.1765, 299.1813, 271.2283, 255.2118, | Demethylation | 1.3644 | + | ||||
| M4 | C19H26O4 | 317.1764 | 29.34 | 1.7 | 317.1764, 299.1816, 271.2292, 255.2122, | Demethylation | 1.3644 | + | ||||
| M5 | C19H28O3 | 303.1972 | 14.41 | 2.2 | 303.1972, 285.0737, 267.1234, | Loss of CO | 2.3380 | + | ||||
| M6 | C20H28O3 | 315.1973 | 28.53 | 2.2 | 315.1973, 297.1815, 269.0817, | Loss of O | 2.5922 | + | + | + | + | |
| M7 | C20H28O3 | 315.1968 | 29.11 | 0.7 | 315.1968, 297.1877, 269.0833, 253.0732, 133.0302, | Loss of O | 2.1212 | + | + | + | + | |
| M8 | C20H30O4 | 333.2078 | 23.01 | 1.9 | 333.2078, 315.1951, 287.1812, 271.1692, 151.0767, | Hydrogenation | 2.2348 | + | + | |||
| M9 | C20H30O4 | 333.2081 | 20.13 | 2.8 | 333.2081, 315.1960, 151.1134, | Hydrogenation | 2.9720 | + | ||||
| M10 | C20H30O4 | 333.2079 | 20.43 | 2.0 | 333.2079, 315.1968, 287.1327, 271.1692, | Hydrogenation | 2.2854 | + | ||||
| M11 | C20H30O5 | 349.2020 | 11.23 | −0.2 | 349.2020, 331.1912, 303.1963, 287.2022, 167.1065, | Internal hydrolysis | 1.0482 | + | + | |||
| M12 | C20H26O4 | 329.1760 | 18.34 | 0.5 | 329.1760, 311.0892, 283.1180, 267.1007, 147.0371, | Desaturation | 1.6594 | + | + | + | ||
| M13 | C20H26O4 | 329.1765 | 18.05 | 1.8 | 329.1765, 311.2208, 283.2639, 267.1934, | Desaturation | 1.7394 | + | + | + | ||
| M14 | C20H26O6 | 361.1657 | 24.42 | 0.1 | 361.1657, 343.1899, 315.1971, 299.2137, | Oxidation to carboxylic acid | 0.6694 | + | + | * | ||
| M15 | C20H28O5 | 347.1866 | 3.01 | 0.6 | 347.1866, 329.1686, 301.1778, 285.1866, | Mono-oxidation | 1.1712 | + | + | + | ||
| M16 | C20H28O5 | 347.1874 | 4.02 | 2.8 | 347.1874, 329.2308, 301.1415, 285.1857, 165.1280, 147.0799 | Mono-oxidation | 1.8424 | + | + | + | ||
| M17 | C20H28O5 | 347.1859 | 22.25 | −1.4 | 347.1859, 329.1782, 301.2046, 285.1864, | Mono-oxidation | 0.5968 | + | + | + | ||
| M18 | C20H28O6 | 363.1821 | 11.62 | 2.1 | 363.1821, 345.1675, 317.2071, 301.1773, 165.0883 | Di-oxidation | 0.5558 | + | + | + | ||
| M19 | C20H28O6 | 363.1826 | 13.25 | 3.7 | 363.1821, 345.1675, 317.2073, 301.1771, 165.0882 | Di-oxidation | 1.1302 | + | + | + | ||
| M20 | C20H28O7 | 379.1753 | 23.14 | −2.6 | 379.1753, 361.2113, 333.2042, 317.1679, 165.1244, 139.1135 | Tri-oxidation | −1.5640 | + | + | * | ||
| M21 | C20H28O7 | 345.1701 | 7.98 | −1.9 | 345.1701, 327.2164, 299.1661, 283.1735, 137.0965, | Ketone formation | 1.2740 | + | + | |||
| M22 | C20H26O5 | 345.1704 | 8.23 | −1.0 | 345.1704, 327.2086, 299.1842, 283.0953, | Ketone formation | 0.4673 | + | + | |||
| M23 | C20H26O5 | 345.1702 | 8.44 | −1.6 | 345.1717, 327.2098, 299.1796, 283.1672, 163.0760 | Ketone formation | 1.0298 | + | + | |||
| M24 | C19H26O5 | 333.1689 | 24.48 | −5.4 | 333.1689, 315.1580, 287.1633, 271.1687, 165.0540, | Demethylation and oxidation | 1.3223 | + | ||||
| M25 | C20H26O5 | 333.1691 | 25.25 | −4.9 | 333.1691, 315.1671, 287.1503, 271.1730, 165.0931, 107.0431 | Demethylation and oxidation | 1.3234 | + | ||||
| M26 | C19H26O6 | 349.1632 | 8.62 | −6.0 | 349.1636, 331.1516, 303.1963, 287.1991 | Demethylation and di-oxidation | −0.6344 | + | ||||
| M27 | C19H26O6 | 349.1636 | 8.74 | −5.8 | 349.1636, 331.1516, 303.1963, 287.1991 | Demethylation and di-oxidation | 0.0368 | + | ||||
| M28 | C19H26O6 | 349.1650 | 8.83 | −1.9 | 349.1636, 331.1516, 303.1963, 287.1991 | Demethylation and di-oxidation | 0.6112 | + | ||||
| M29 | C19H28O4 | 319.1910 | 12.21 | −1.5 | 319.1913, 301.1800, 273.1723, 257.1903, 151.0537 | Demethylation and hydrogenation | 1.7158 | + | + | |||
| M30 | C19H28O4 | 319.1913 | 12.44 | −0.4 | 319.1913, 301.1800, 273.1723, 257.1903, 151.0537 | Demethylation and hydrogenation | 1.7158 | + | + | |||
| M31 | C20H30O6 | 365.1962 | 18.90 | −2.1 | 365.1962, 347.1867, 319.1932, 303.1956, 167.0678, | Oxidation and internal hydrolysis | 0.3359 | + | + | |||
| M32 | C20H30O7 | 381.1920 | 13.25 | 0.2 | 381.1920, 363.1791, 335.1438, 319.1531, 167.0665, | Di-oxidation and internal hydrolysis | −0.9506 | + | + | + | ||
| M33 | C21H30O4 | 345.2100 | 18.92 | 1.7 | 345.2100, 327.1601, 299.1634, 283.1699, 163.0399, | Methylation | 2.0116 | + | ||||
| M34 | C21H30O4 | 345.2101 | 19.87 | 1.7 | 345.2101, 327.1600, 299.1647, 283.1673, | Methylation | 1.9848 | + | ||||
| M35 | C20H28O7S | 411.1499 | 5.62 | 3.9 | 411.1499, 393.1781, 365.1366, 349.1960, 229.0632, | Sulfate conjugation | 1.1902 | + | * | |||
| M36 | C20H28O7S | 411.1490 | 5.75 | 1.6 | 411.1490, 393.1571, 365.2022, 349.1958, | Sulfate conjugation | 1.1812 | + | ||||
| M37 | C20H28O8S | 427.1424 | 10.66 | −2.0 | 427.1424, 409.2193, 381.1955, 365.2184, 165.0637, | Oxidation and sulfate conjugation | 1.1402 | + | ||||
| M38 | C26H38O9 | 493.2049 | 9.87 | −6.2 | 493.2049, 475.2261, 447.2853, 175.0731, | Demethylation and glucuronide conjugation | −0.6910 | + | * | |||
| Total | 7 | 25 | 18 | 17 | 7 |
RIF: rat intestinal flora; U: urine; F: feces; B: bile; P: plasma. Total: total metabolites. KPIs were indicated in bold face. “+”: the MS data detected by DDA and DIA. “*”: the MS data only detected by DIA. The MS/MS fragment data of M1, M2, M8, M9, M10 could only be observed under DDA mode.
Fig. 4TIC for the experimental group in vivo. (Panel U: the group in urine by DDA; Panel F: the group in feces by DDA; Panel B: the group in bile by DDA; Panel P: the group in plasma by DIA.)
Fig. 6The EIC and MS/MS spectra of metabolites in vitro, including M11, M14, M18, M19, M32, M33, M34.
Fig. 7The EIC of M33, M34in vitro (Panel A: the RIF sample group; Panel B: blank B group; Panel C: blank C group).